Literature DB >> 2537588

Dose-response relation and time course of action of pipecuronium bromide in humans anesthetized with nitrous oxide and isoflurane, halothane, or droperidol and fentanyl.

J M Wierda1, F J Richardson, S Agoston.   

Abstract

The dose-response of pipecuronium bromide, the time course of its neuromuscular blocking effects, and the reversibility of the residual block by neostigmine and edrophonium have been investigated in patients undergoing various types of anesthesia. The estimated doses of pipecuronium required for 95% depression of the twitch height were 44.6, 46.9, and 48.7 micrograms.kg-1 during anesthesia with nitrous oxide (65%) and isoflurane (group 1), halothane (group 2), or droperidol/fentanyl (group 3), respectively. The potentiating effects of the volatile anesthetics were reflected by the significant prolongation of the duration of both initial (50.0 +/- 4.3, 36.0 +/- 3.3, and 29.0 +/- 2.0 minutes) and maintenance doses (56.0 +/- 2.5, 49.5 +/- 3.3, and 41.2 +/- 1.6 minutes) of pipecuronium during anesthesia with nitrous oxide and isoflurane, halothane, or droperidol/fentanyl, respectively. Both edrophonium chloride (0.5 mg.kg-1) and neostigmine methylsulphate (40 micrograms.kg-1) promptly reversed the residual block induced by pipecuronium. No side effects attributable to pipecuronium were seen in this study.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2537588

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  8 in total

Review 1.  Which drug--steroid or benzylisoquinolinium?

Authors:  B J Pollard
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

Review 2.  Neuromuscular transmission and its pharmacological blockade. Part 1: Neuromuscular transmission and general aspects of its blockade.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

Review 3.  Newer neuromuscular blocking drugs. An overview of their clinical pharmacology and therapeutic use.

Authors:  R K Mirakhur
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

4.  Dose-response relation and time course of action of pipecuronium in patients anesthetized with nitrous oxide and sevoflurane.

Authors:  N Ueda; Y Masuda; T Muteki; K Ohishi; K Tayama; N Yamashita
Journal:  J Anesth       Date:  1993-04       Impact factor: 2.078

5.  Neuromuscular effects of pipecuronium during sevoflurane anesthesia compared with isoflurane and enflurane anesthesia.

Authors:  Y Nakao; M Ohno; M Imai; O Kemmotsu
Journal:  J Anesth       Date:  1993-10       Impact factor: 2.078

6.  Edrophonium priming alters the course of neuromuscular recovery from a pipecuronium neuromuscular blockade.

Authors:  M Naguib; M Abdulatif
Journal:  Can J Anaesth       Date:  1991-09       Impact factor: 5.063

7.  Neostigmine and edrophonium for reversal of pipecuronium neuromuscular blockade.

Authors:  M Abdulatif; M Naguib
Journal:  Can J Anaesth       Date:  1991-03       Impact factor: 5.063

8.  Left ventricular regional wall motion and haemodynamic changes following bolus administration of pipecuronium or pancuronium to adult patients undergoing coronary artery bypass grafting.

Authors:  G D Shorten; T Sieber; A D Maslow; J M Haering; L K Robertson; M E Comunale
Journal:  Can J Anaesth       Date:  1995-08       Impact factor: 5.063

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.